M&A Deal Summary

Novo Nordisk A/S Acquires MB2

On August 27, 2015, Novo Nordisk A/S acquired life science company MB2

Acquisition Highlights
  • This is Novo Nordisk A/S’s 2nd transaction in the Life Science sector.
  • This is Novo Nordisk A/S’s 2nd transaction in the United States.
  • This is Novo Nordisk A/S’s 2nd transaction in Indiana.

M&A Deal Summary

Date 2015-08-27
Target MB2
Sector Life Science
Buyer(s) Novo Nordisk A/S
Deal Type Add-on Acquisition

Target

MB2

Carmel, Indiana, United States
MB2 LLC is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class, mixed agonist drugs for the treatment of diabetes and obesity.

Search 177,612 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Novo Nordisk A/S

Bagsvaerd,, Denmark

website


Category Company
Founded 1925
Sector Life Science
Employees39,062
DESCRIPTION

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Company has experience and capabilities that enable to help people defeat other serious chronic conditions, haemophilia, growth disorders and obesity.


DEAL STATS #
Overall 2 of 6
Sector (Life Science) 2 of 6
Type (Add-on Acquisition) 2 of 6
State (Indiana) 2 of 2
Country (United States) 2 of 5
Year (2015) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-08-27 Calibrium

Indianapolis, Indiana, United States

Calibrium LLC is a biopharmaceutical company focused on the discovery and early development of novel peptides for the treatment of diabetes and related metabolic diseases.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-08-17 Ziylo

Bristol, United Kingdom

Ziylo is a supramolecular chemistry company that has developed a third 'biomimetic' class of glucose binding molecules (GBMs). These molecules have potential to be a critical component in medical devices such as Continuous Glucose Monitors (CGM) and therapeutics such as Glucose Responsive Insulins (GRIs). Ziylo was founded in 2014 and is based in Bristol, United Kingdom.

Buy $800M